Your browser doesn't support javascript.
loading
Dynamics of Epstein-Barr virus after cord blood transplantation: A nationwide survey in Japan.
Sawada, Akihisa; Taniguchi, Shuichi; Takahashi, Satoshi; Inoue, Masami; Onishi, Yasushi; Tanaka, Masatsugu; Henzan, Hideho; Kubo, Masayuki; Nishida, Aya; Kawa, Keisei.
Afiliación
  • Sawada A; Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.
  • Taniguchi S; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Takahashi S; Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Inoue M; Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.
  • Onishi Y; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
  • Tanaka M; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
  • Henzan H; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Kubo M; Department of Respiratory Medicine, Allergology and Hematology, Nara Medical University Hospital, Kashihara, Japan.
  • Nishida A; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Kawa K; Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.
Blood Cell Ther ; 4(1): 9-14, 2021 Feb 25.
Article en En | MEDLINE | ID: mdl-36712842
Epstein-Barr virus (EBV) is a common virus that latently infects most adults and has a tropism to B lymphocytes. In 1988, two cases of EBV infection were reported to be eradicated by hematopoietic stem cell transplantation from an EBV-negative donor. However, the dynamics of EBV after cord blood transplantation (CBT), namely, the kinetics of anti-EBV antibodies, the incidence of negative/adverse seroconversion (from positive to negative), and the clinical course of re-infection (second primary infection) by EBV, have not yet been characterized in detail. Therefore, we performed a nationwide survey that focused on the dynamics of EBV after CBT 1 year or later after CBT. Negative seroconversion occurred in 23% of previously EBV-infected patients. The incidence of late-onset EBV-associated events was 1.9% (13/674): 5 infectious mononucleosis, 2 hemophagocytic lymphohistiocytosis (HLH), and 6 remaining typical lymphoproliferative disease. HLH occurred in newly infected patients (primary or second primary) and also in those with reactivation and was fatal. The annual monitoring of anti-EBV antibody titers may facilitate the early detection of these late-onset EBV-associated events and treatment initiation before disease progression.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Screening_studies Idioma: En Revista: Blood Cell Ther Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Screening_studies Idioma: En Revista: Blood Cell Ther Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón